Twentyeight-Seven Therapeutics
https://www.twentyeight-seven.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Twentyeight-Seven Therapeutics
Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019
An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.
Start-Up Quarterly Statistics: Q3 Financings Slump Despite Large Gossamer Series B, Big Rubius IPO
Third quarter biopharma start-up financing activity decreased from the record-breaking Q2. A review of biopharma start-up dealmaking and financing activity from July through September 2018, based on data from Strategic Transactions.
Venture Funding Deals: Atreca Raises $125m To Advance Solid Tumor Candidate
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August and September.
Deals Shaping The Medical Industry, June 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.
Company Information
- Industry
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- 28-7 Therapeutics